×
About 7,103 results

ALLMedicine™ Aspartate Aminotransferase Center

Research & Reviews  2,646 results

Predictive performance of eLIFT for liver inflammation and fibrosis in chronic liver di...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436088
International Journal of Medical Sciences; Yang Z, Ma X et. al.

Sep 16th, 2021 - Objective: The easy liver fibrosis test (eLIFT) is a novel predictor of liver fibrosis in chronic liver disease (CLD). This study aimed to evaluate the predictive value of the eLIFT for liver inflammation and fibrosis in CLD patients. Methods: We ...

The effects of 7000 meter race on haematological and biochemical parameters in racing g...
https://doi.org/10.1016/j.tcam.2021.100583
Topics in Companion Animal Medicine; Tharwat M, Al-Sobayil F

Sep 14th, 2021 - This study was carried out to investigate the effects of 7000 meter race on haematological and biochemical profiles in racing greyhounds. Thirty-two male racing greyhounds were enrolled in this study. Blood samples were collected from the greyhoun...

Relationships of Dietary Habits and Physical Activity Status with Non-Alcoholic Fatty L...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431170
International Journal of Environmental Research and Publi... Yabe Y, Kim T et. al.

Sep 11th, 2021 - (1) Aim: Hepatic fibrosis is a prognostic factor for disease progression in non-alcoholic fatty liver disease (NAFLD). We aimed to determine the relationships between diet, physical activity, and the progression of liver fibrosis. (2) Methods: The...

MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treat...
https://doi.org/10.1002/hep.32145
Hepatology (Baltimore, Md.); Tamaki N, Imajo K et. al.

Sep 9th, 2021 - Nonalcoholic fatty liver disease (NAFLD) patients with significant hepatic fibrosis (stage ≥ 2) are at increased risk of liver-related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of ...

Association of elevated serum aminotransferase levels with chronic kidney disease measu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422630
BMC Nephrology; Missikpode C, Kramer H et. al.

Sep 9th, 2021 - Previous studies have shown an association between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD), but it is unclear whether the association is independent of metabolic syndrome. Data from 13,006 participants aged 18 to...

see more →

Guidelines  1 results

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

see more →

Drugs  35 results see all →

Clinicaltrials.gov  1 results

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
https://clinicaltrials.gov/ct2/show/NCT01329562

Apr 9th, 2014 - This double-blind multi-site study will be conducted to enroll 40 evaluable participants. All subjects will be medically stable at enrollment and be on a stabilized dosage of daily medications. At Visit 1 (Baseline) following Informed Consent, a p...

see more →

News  158 results

Adverse Events in HER2-Positive Metastatic Breast Cancer Treatment
https://www.onclive.com/view/adverse-events-in-her2-positive-metastatic-breast-cancer-treatment

Jul 15th, 2021 - Sara A. Hurvitz, MD: Longer-term safety data were also presented at ASCO [the American Society of Clinical Oncology annual meeting] for the HER2CLIMB trial. The safety data were reassuring; there were no new safety events or signals that were pick...

FDA Grants Regular Approval to Enfortumab Vedotin, Expands Indication for Locally Advanced or Metastatic Urothelial Cancer
https://www.onclive.com/view/fda-grants-regular-approval-to-enfortumab-vedotin-expands-indication-for-locally-advanced-or-metastatic-urothelial-cancer

Jul 9th, 2021 - The FDA has granted a regular approval to enfortumab vedotin-ejfv (Padcev) and has expanded the agent's indication to include adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemothe...

Zandelisib/Zanubrutinib Yields Promising Responses in R/R CLL, and B-cell Malignancies
https://www.onclive.com/view/zandelisib-zanubrutinib-yields-promising-responses-in-r-r-cll-and-b-cell-malignancies

Jun 11th, 2021 - A 60 mg dose of zandelisib (ME-401) administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib (Brukinsa) twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymph...

Single Agent and Combination TG-1701 Yield Promising Clinical Activity in CLL and Other B-Cell Malignancies
https://www.onclive.com/view/single-agent-and-combination-tg-1701-yield-promising-clinical-activity-in-cll-and-other-b-cell-malignancies

Jun 5th, 2021 - TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies, according to updated results from a phase 1/2 trial (NCT03671590) that were presented virtually during the 2021 ASCO An...

Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors
https://www.onclive.com/view/pralsetinib-elicits-durable-anti-tumor-effects-in-ret-fusion-solid-tumors

Jun 5th, 2021 - Pralsetinib (Gavreto) demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors, according to updated findings from the ARROW ...

see more →